Items Tagged ‘trial’

December 20th, 2016

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

By

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggests that treatment with Jakafi should be used much earlier in the course of a patient’s disease because it […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, American Society of Hematology, ASH, COMFORT-I, COMFORT-II, essential thrombocythemia, jakafi, MF, mpn, myelofibrosis, myeloproliferative neoplasm


November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


February 29th, 2016

Arzerra® Approved as Maintenance Therapy for Advanced CLL

By

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not received prior therapy, or whose CLL has stopped responding to prior therapies. CLL is a type of cancer […]

View full entry

Tags: arzerra, B-cells, biologic agent, CD-20, Chronic Lymphoblastic Leukemia, chronic lymphocytic, CLL, fda, Leukemia, News, ofatumumab, PROLONG